Our highly translational studies, using global Nampt+/− heterozygous knockout mice, an iNAMPT enzymatic inhibitor and an eNAMPT-neutralising mAb, indicate that NAMPT is a promising therapeutic target for developing novel and unique treatments for CMD in people with diabetes. Here, NAMPT is linked to diabetes mellitus.